Enterprise Value

508.4M

Cash

95.1M

Avg Qtr Burn

-20.16M

Short % of Float

6.20%

Insider Ownership

2.71%

Institutional Own.

42.72%

Qtr Updated

03/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Approved

Quarterly sales

RECORLEV (levoketoconazole) Details
Rare diseases, Cushing’s syndrome

Approved

Quarterly sales

Approved

Quarterly sales

Phase 2

Initiation

Gvoke RTU Micro™ Details
Hypoglycemia, Type 1 diabetes, Type 2 diabetes

Failed

Discontinued

Pramlintide-Insulin Details
Type 1 diabetes, Diabetes, Type 2 diabetes

Failed

Discontinued

Failed

Discontinued